Cyclin D mediates tolerance of genome-doubling in cancers with functional p53

Annals of Oncology

Volumn 28, Issue 1, 2017, Pages 149-156

  Crockford, A ^a   Zalmas, L P ^a   Gronroos E ^a   Dewhurst, S M ^a   McGranahan, N ^a   Cuomo, M E ^a   Encheva, V ^a   Snijders, A P ^a   Begum, J ^a   Purewal, S ^a   Cerveira, J ^a   Patel, H ^a   Renshaw, M J ^a   Swanton, C ^a  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

Chromosomal instability; Cyclin D; P21; P53; Tetraploidy

Indexed keywords

ABEMACICLIB; CYCLIN D; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PROTEIN P21; PROTEIN P53; 5-(4-ETHYLPIPERAZIN-1-YLMETHYL)PYRIDIN-2-YL)-(5-FLUORO-4-(7-FLUORO-3-ISOPROPYL-2-METHYL-3H-BENZIMIDAZOL-5-YL)PYRIMIDIN-2-YL)AMINE; AMINOPYRIDINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CCNC PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN C; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOCHALASIN B; DIHYDROCYTOCHALASIN B; PROTEIN KINASE INHIBITOR; TP53 PROTEIN, HUMAN;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIPLOIDY; ENZYME ACTIVITY; GENE DUPLICATION; GENE OVEREXPRESSION; MALIGNANT NEOPLASM; MOLECULAR CLONING; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; TETRAPLOIDY; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COLORECTAL TUMOR; FLOW CYTOMETRY; GENE KNOCKDOWN; GENETICS; HCT 116 CELL LINE; HUMAN; METABOLISM; TUMOR CELL LINE;

ADENOCARCINOMA; AMINOPYRIDINES; BENZIMIDAZOLES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLIN C; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOCHALASIN B; DIPLOIDY; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; GENES, P53; HCT116 CELLS; HUMANS; PROTEIN KINASE INHIBITORS; TETRAPLOIDY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85015769028     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw612     Document Type: Article

References (26)

1. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C et al. Clonogenic assay of cells in vitro. Nature protocols 2006; 1(5): 2315-2319. Epub 2007/04/05. doi: 10.1038/nprot.2006.339. PubMed PMID: 17406473.
2. Thompson SL, Compton DA. Proliferation of aneuploid human cells is limited by a p53-dependentmechanism. J Cell Biol 2010; 188(3): 369-381.
3. Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 2007; 17(2): 157-162.
4. Andreassen PR, Lohez OD, Lacroix FB, Margolis RL. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell 2001; 12(5): 1315-1328.
5. Di Leonardo A, Khan SH, Linke SP et al. Rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 1997; 57(6): 1013-1019.
6. Aylon Y, Oren M. New plays in the p53 theater. Curr Opin Genet Dev 2011; 21(1): 86-92.
7. Galipeau PC, Cowan DS, Sanchez CA et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA 1996; 93(14): 7081-7084.
8. Fujiwara T, Bandi M, Nitta M et al. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 2005; 437(7061): 1043-1047.
9. Dewhurst SM, McGranahan N, Burrell RA et al. Tolerance of wholegenome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov 2014; 4(2): 175-185.
10. McGranahan N, Favero F, de Bruin EC et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med 2015; 7(283): 283ra54.
11. Davoli T, de Lange T. The causes and consequences of polyploidy in normal development and cancer. Annu Rev Cell Dev Biol 2011; 27(1): 585-610.
12. Parsons R, Li GM, Longley MJ et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993; 75(6): 1227-1236.
13. Ganem NJ, Cornils H, Chiu SY et al. Cytokinesis failure triggers hippo tumor suppressor pathway activation. Cell 2014; 158(4): 833-848.
14. Sakaue-Sawano A, Kurokawa H, Morimura T et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008; 132(3): 487-498.
15. Musgrove EA, Caldon CE, Barraclough J et al. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11(8): 558-572.
16. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3(5): 330-338.
17. Meek DW. Regulation of the p53 response and its relationship to cancer. Biochem J 2015; 469(3): 325-346.
18. Matson DR, Stukenberg PT. Spindle poisons and cell fate: a tale of two pathways. Mol Interv 2011; 11(2): 141-150.
19. Elangovan S, Hsieh TC, Wu JM. Growth inhibition of human MDA-mB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product. Anticancer Res 2008; 28(5A): 2641-2647.
20. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9(6): 400-414.
21. Hall M, Bates S, Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 1995; 11(8): 1581-1588.
22. LaBaer J, Garrett MD, Stevenson LF et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997; 11(7): 847-862.
23. O'Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol 2016; 13(7): 417-430.
24. Potapova TA, Seidel CW, Box AC et al. Transcriptome analysis of tetraploid cells identifies Cyclin D2 as a facilitator of adaptation to genome doubling in the presence of p53. Mol Biol Cell 2016;27(20): 3065-3084.
25. Planas-Silva MD, Weinberg RA. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 1997; 17(7): 4059-4069.
26. Arkin MR, Tang Y, Wells JA. Small-molecule inhibitors of proteinprotein interactions: progressing toward the reality. Chem Biol 2014; 21(9): 1102-1114.